|1.||Watson, A J: 5 articles (10/2010 - 11/2005)|
|2.||Margison, G P: 5 articles (10/2010 - 11/2005)|
|3.||Middleton, M R: 4 articles (10/2010 - 05/2008)|
|4.||Mortimer, P: 4 articles (10/2010 - 05/2008)|
|5.||Middleton, Mark R: 3 articles (01/2010 - 03/2006)|
|6.||Margison, Geoffrey P: 3 articles (01/2010 - 03/2006)|
|7.||Ranson, M: 3 articles (04/2009 - 05/2008)|
|8.||Castresana, Javier S: 2 articles (02/2014 - 06/2013)|
|9.||Taspinar, Mehmet: 2 articles (02/2014 - 06/2013)|
|10.||Rey, Juan A: 2 articles (02/2014 - 06/2013)|
|1.||Melanoma (Melanoma, Malignant)
04/21/2009 - "Patients with unresectable stage 3 or 4 cutaneous or unknown primary melanoma metastases were treated with lomeguatrib 40 mg, b.i.d. "
09/06/2011 - "Inhibition of DNA repair with MGMT pseudosubstrates: phase I study of lomeguatrib in combination with dacarbazine in patients with advanced melanoma and other solid tumours."
04/21/2009 - "We evaluated the pharmacodynamic effects of the O(6)-methylguanine-DNA methyltransferase (MGMT) inactivator lomeguatrib (LM) on patients with melanoma in two clinical trials. "
04/21/2009 - "A phase I study of extended dosing with lomeguatrib with temozolomide in patients with advanced melanoma."
06/20/2007 - "Randomized trial of the combination of lomeguatrib and temozolomide compared with temozolomide alone in chemotherapy naive patients with metastatic cutaneous melanoma."
|2.||Colorectal Neoplasms (Colorectal Cancer)
01/15/2010 - "Total MGMT inactivation can be achieved in prostate, primary CNS, and colorectal cancers with a single administration of 120 or 160 mg lomeguatrib. "
01/15/2010 - "Consistent total MGMT inactivation required 120 mg of lomeguatrib in prostate and colorectal cancers. "
01/15/2010 - "We sought to determine the dose of oral 6-(4-bromo-2-thienyl) methoxy purin-2-amine (lomeguatrib), a pseudosubstrate inactivator of MGMT, required to render active protein undetectable 12 hours after dosing in prostate, primary central nervous system (CNS), and colorectal cancer patients. "
05/20/2008 - "This combination of lomeguatrib and TMZ is not efficacious in metastatic colorectal cancer. "
05/20/2008 - "Patients with stage IV metastatic colorectal carcinoma received lomeguatrib (40 mg) and TMZ (50-200 mg m(-2)) orally for 5 consecutive days every 4 weeks. "
01/15/2010 - "Complete consistent inactivation in CNS tumors was observed only at the highest dose of lomeguatrib (160 mg). "
01/15/2010 - "Thirty-seven patients were dosed with lomeguatrib, and 32 informative tumor samples were obtained. "
01/15/2010 - "Lomeguatrib was administered orally as a single dose (20-160 mg) approximately 12 hours before tumor resection. "
03/01/2006 - "More than 95% ATase depletion within 4 hours of the first dose was achieved in peripheral blood mononuclear cells at lomeguatrib doses of > or =10 mg/m2/d i.v. or > or =20 mg/m2/d orally, and tumor biopsies showed > or =92% ATase depletion. "
03/01/2006 - "The main aims of this phase I trial were to determine an ATase-depleting dose (ADD) of lomeguatrib, a potent pseudosubstrate inhibitor, and to define a suitable dose of temozolomide to be used in combination with lomeguatrib in patients with advanced cancer. "
06/20/2007 - "To evaluate tumor response, pharmacodynamic effects, and safety of a combination of lomeguatrib (LM), an O6-methylguanine DNA-methyltransferase (MGMT) inactivator, and temozolomide (TMZ), TMZ alone, and LM/TMZ after disease progression on TMZ alone in patients with advanced melanoma. "
|5.||Neoplasm Metastasis (Metastasis)
|7.||DNA (Deoxyribonucleic Acid)
|1.||Drug Therapy (Chemotherapy)
|2.||Heterologous Transplantation (Xenotransplantation)